Damani A Piggott1,2, Abimereki D Muzaale3, Ravi Varadhan4,5, Shruti H Mehta2, Ryan P Westergaard6, Todd T Brown1,2, Kushang V Patel7, Jeremy D Walston1, Sean X Leng1, Gregory D Kirk1,2. 1. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2. Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, Maryland. 3. Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland. 4. Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland. 5. Department of Biostatistics, Johns Hopkins University School of Public Health, Baltimore, Maryland. 6. Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison. 7. Department of Anesthesiology and Pain Medicine, University of Washington School of Medicine, Seattle.
Abstract
Background: Hospitalization events exact a substantial toll across the age spectrum. Frailty is associated with all-cause hospitalization among HIV-uninfected adults aged 65 years and older. Limited data exist on the frailty relationship to hospitalization among HIV-infected persons or those aged less than 65 years. Comparative investigation of the frailty relationship to specific classes of hospitalizations has rarely been reported among adults of any age. This study sought to determine the frailty relationship to three distinct classes of hospitalization events among HIV-infected persons and their uninfected counterparts. Methods: Frailty was ascertained semiannually among persons with prior injection drug use using the five Fried phenotypic domains. Hospitalization events were categorized using Agency for Healthcare Research and Quality clinical classification software into chronic, infectious, and nonchronic, noninfectious conditions. Cox proportional hazards models were used to examine the frailty relationship to time to first hospitalization event. Results: Among 1,303 subjects, mean age was 48 years; 32% were HIV-infected. Adjusting for sociodemographics, comorbidity, substance use, and HIV disease stage, time-updated frailty status was associated with risk for all hospitalization classes. Baseline frailty was significantly associated with all-cause (hazards ratio [HR] 1.41; 95% confidence interval [CI], 1.06, 1.87), chronic (HR 2.13; 95% CI, 1.46, 3.11), and infectious disease hospitalization (HR 2.51; 95% CI, 1.60, 3.91) but not with nonchronic, noninfectious hospitalization risk (HR 1.09; 95% CI, 0.74, 1.61). Conclusion: The frailty phenotype predicts vulnerability to chronic and infectious disease-related hospitalization. Frailty-targeted interventions may mitigate the substantial burden of infectious and chronic disease-related morbidity and health care utilization in HIV-infected and uninfected populations.
Background: Hospitalization events exact a substantial toll across the age spectrum. Frailty is associated with all-cause hospitalization among HIV-uninfected adults aged 65 years and older. Limited data exist on the frailty relationship to hospitalization among HIV-infectedpersons or those aged less than 65 years. Comparative investigation of the frailty relationship to specific classes of hospitalizations has rarely been reported among adults of any age. This study sought to determine the frailty relationship to three distinct classes of hospitalization events among HIV-infectedpersons and their uninfected counterparts. Methods: Frailty was ascertained semiannually among persons with prior injection drug use using the five Fried phenotypic domains. Hospitalization events were categorized using Agency for Healthcare Research and Quality clinical classification software into chronic, infectious, and nonchronic, noninfectious conditions. Cox proportional hazards models were used to examine the frailty relationship to time to first hospitalization event. Results: Among 1,303 subjects, mean age was 48 years; 32% were HIV-infected. Adjusting for sociodemographics, comorbidity, substance use, and HIV disease stage, time-updated frailty status was associated with risk for all hospitalization classes. Baseline frailty was significantly associated with all-cause (hazards ratio [HR] 1.41; 95% confidence interval [CI], 1.06, 1.87), chronic (HR 2.13; 95% CI, 1.46, 3.11), and infectious disease hospitalization (HR 2.51; 95% CI, 1.60, 3.91) but not with nonchronic, noninfectious hospitalization risk (HR 1.09; 95% CI, 0.74, 1.61). Conclusion: The frailty phenotype predicts vulnerability to chronic and infectious disease-related hospitalization. Frailty-targeted interventions may mitigate the substantial burden of infectious and chronic disease-related morbidity and health care utilization in HIV-infected and uninfected populations.
Authors: Kevin P High; Mark Brennan-Ing; David B Clifford; Mardge H Cohen; Judith Currier; Steven G Deeks; Sherry Deren; Rita B Effros; Kelly Gebo; Jörg J Goronzy; Amy C Justice; Alan Landay; Jules Levin; Paolo G Miotti; Robert J Munk; Heidi Nass; Charles R Rinaldo; Michael G Shlipak; Russell Tracy; Victor Valcour; David E Vance; Jeremy D Walston; Paul Volberding Journal: J Acquir Immune Defic Syndr Date: 2012-07-01 Impact factor: 3.731
Authors: Jeremy Walston; Evan C Hadley; Luigi Ferrucci; Jack M Guralnik; Anne B Newman; Stephanie A Studenski; William B Ershler; Tamara Harris; Linda P Fried Journal: J Am Geriatr Soc Date: 2006-06 Impact factor: 5.562
Authors: Xu Yao; Robert G Hamilton; Nan-ping Weng; Qian-Li Xue; Jay H Bream; Huifen Li; Jing Tian; Shu-Hui Yeh; Barbara Resnick; Xiyan Xu; Jeremy Walston; Linda P Fried; Sean X Leng Journal: Vaccine Date: 2011-05-10 Impact factor: 3.641
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: Christopher Rentsch; Janet P Tate; Kathleen M Akgün; Stephen Crystal; Karen H Wang; S Ryan Greysen; Emily A Wang; Kendall J Bryant; David A Fiellin; Amy C Justice; David Rimland Journal: AIDS Behav Date: 2016-03
Authors: Kate Buchacz; Rose K Baker; Anne C Moorman; James T Richardson; Kathleen C Wood; Scott D Holmberg; John T Brooks Journal: AIDS Date: 2008-07-11 Impact factor: 4.177
Authors: Brian J Buta; Jeremy D Walston; Job G Godino; Minsun Park; Rita R Kalyani; Qian-Li Xue; Karen Bandeen-Roche; Ravi Varadhan Journal: Ageing Res Rev Date: 2015-12-07 Impact factor: 10.895
Authors: Kellie L Hawkins; Long Zhang; Derek K Ng; Keri N Althoff; Frank J Palella; Lawrence A Kingsley; Lisa P Jacobson; Joseph B Margolick; Jordan E Lake; Todd T Brown; Kristine M Erlandson Journal: AIDS Date: 2018-06-19 Impact factor: 4.177
Authors: Anna A Rubtsova; María J Marquine; Colin Depp; Marcia Holstad; Ronald J Ellis; Scott Letendre; Dilip V Jeste; David J Moore Journal: Behav Med Date: 2018-11-15 Impact factor: 3.104
Authors: Junichi Ishigami; Ron C Hoogeveen; Christie M Ballantyne; Aaron R Folsom; Josef Coresh; Elizabeth Selvin; Kunihiro Matsushita Journal: Am J Epidemiol Date: 2019-12-31 Impact factor: 4.897
Authors: David W Sosnowski; Kenneth A Feder; Jacquie Astemborski; Becky L Genberg; Elizabeth J Letourneau; Rashelle J Musci; Ramin Mojtabai; Lisa McCall; Eileen Hollander; Lynnet Loving; Brion S Maher; Gregory D Kirk; Shruti H Mehta; Jing Sun Journal: BMC Public Health Date: 2022-05-16 Impact factor: 4.135
Authors: Ruibin Wang; Michael G Shlipak; Joachim H Ix; Todd T Brown; Lisa P Jacobson; Frank J Palella; Jordan E Lake; Susan L Koletar; Richard D Semba; Michelle M Estrella Journal: J Acquir Immune Defic Syndr Date: 2019-01-01 Impact factor: 3.731
Authors: Fátima Brañas; Mª José Galindo; Miguel Torralba; Antonio Antela; Jorge Vergas; Margarita Ramírez; Pablo Ryan; Fernando Dronda; Carmen Busca; Isabel Machuca; Mª Jesús Bustinduy; Alfonso Cabello; Matilde Sánchez-Conde Journal: PLoS One Date: 2022-03-30 Impact factor: 3.240
Authors: Thomas D Brothers; Susan Kirkland; Olga Theou; Stefano Zona; Andrea Malagoli; Lindsay M K Wallace; Chiara Stentarelli; Cristina Mussini; Julian Falutz; Giovanni Guaraldi; Kenneth Rockwood Journal: PLoS One Date: 2017-10-05 Impact factor: 3.240
Authors: Eveline Verheij; Gregory D Kirk; Ferdinand W Wit; Rosan A van Zoest; Sebastiaan O Verboeket; Bregtje A Lemkes; Maarten F Schim van der Loeff; Peter Reiss Journal: J Infect Dis Date: 2020-08-17 Impact factor: 5.226